<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article294</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/SOCRATES" style="display:block; margin-bottom:10px;">SOCRATES Original</a></li>
<h2><strong>SOCRATES</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack".<br/>
<br/>
The New England Journal of Medicine. PMID 27160892.<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with acute non-severe ischemic stroke or high-risk transient ischemic attack, is ticagrelor superior to aspirin in preventing recurrent stroke and cardiovascular events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with acute ischemic stroke or transient ischemic attack, ticagrelor is not superior to aspirin in reducing the risk of stroke, myocardial infarction, or death within 90 days.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the knowledge cutoff date, guidelines have not been established that reflect the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Multicenter, double-blind, randomized, controlled trial<br/>
- N=13,199<br/>
- Ticagrelor: n=6,589 (180 mg loading dose, then 90 mg twice daily days 2-90)<br/>
- Aspirin: n=6,610 (300 mg on day 1, then 100 mg daily days 2-90)<br/>
- Setting: 674 centers in 33 countries<br/>
- Enrollment: January 7, 2014 to October 29, 2015<br/>
- Mean follow-up: 90 days<br/>
- Analysis: Intention-to-treat<br/>
- Primary outcome: Stroke (ischemic or hemorrhagic), myocardial infarction, or death within 90 days<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
- Inclusion criteria: Nonsevere ischemic stroke (NIHSS score ≤5) or high-risk TIA (ABCD2 score ≥4 or symptomatic arterial stenosis), ability to start treatment within 24 hours of symptom onset, age ≥40 years, CT or MRI exclusion of intracranial bleeding<br/>
- Exclusion criteria: Need for specific antiplatelet or anticoagulation therapy, planned revascularization within 7 days, history of atrial fibrillation or suspicion of cardioembolic cause, thrombolysis or mechanical thrombectomy within 24 hours before randomization, severe liver disease, renal failure requiring dialysis, pregnancy, or lactation, among others.<br/>
- Baseline characteristics: Median age 65 years, 66.7% male<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Ticagrelor: 180 mg loading dose on day 1 followed by 90 mg twice daily for days 2 through 90<br/>
- Aspirin: 300 mg loading dose on day 1 followed by 100 mg daily for days 2 through 90<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
- Primary outcome occurrence: Ticagrelor, 6.7% (442 patients); Aspirin, 7.5% (497 patients); hazard ratio 0.89; 95% CI, 0.78 to 1.01; P=0.07.<br/>
- Ischemic stroke occurrence: Ticagrelor, 5.8% (385 patients); Aspirin, 6.7% (441 patients); hazard ratio 0.87; 95% CI, 0.76 to 1.00; nominal P=0.046.<br/>
- Safety outcomes: Major bleeding in 0.5% Ticagrelor and 0.6% Aspirin, intracranial hemorrhage in 0.2% Ticagrelor and 0.3% Aspirin, fatal bleeding in 0.1% for both groups.<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
- No ticagrelor benefit in a significant proportion of patients already on aspirin at the time of the qualifying event.<br/>
- Subgroup analysis did not show a significant benefit of ticagrelor over aspirin.<br/>
- Exclusion of patients with a high risk of stroke such as those with carotid or severe intracranial stenosis.<br/>
- Thrombolytic therapy patients were excluded, thus not generalizable to this population.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Funded by AstraZeneca.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Johnston SC, Amarenco P, Albers GW, et al. "Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack". N Engl J Med 2016; 375:35-43. DOI: 10.1056/NEJMoa1603060.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
